Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking approach to diabetes management. These innovative medications function by mimicking the inherent actions of GLP-1, a hormone released by the gut in response to consumption. By stimulating GLP-1 receptors in the pancreas, these compounds enhance insulin release and reduce

The burgeoning landscape of innovative treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight reduction – they exhibit intriguing contrasts in thei